Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria.

Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria. Abstract Text:

Anuradha Alahari,Xavier Trivelli,Yann ,Lynn G Dover,Gurdyal S Besra,James C Sacchettini,Robert C Reynolds,Geoffrey D Coxon,Laurent Kremer,

BACKGROUND: Mycolic acids are a complex mixture of branched, long-chain fatty acids, representing key components of the highly hydrophobic mycobacterial cell wall. Pathogenic mycobacteria carry mycolic acid sub-types that contain cyclopropane rings. Double bonds at specific sites on mycolic acid precursors are modified by the action of cyclopropane mycolic acid synthases (CMASs). The latter belong to a family of S-adenosyl-methionine-dependent methyl transferases, of which several have been well studied in Mycobacterium tuberculosis, namely, MmaA1 through A4, PcaA and CmaA2. Cyclopropanated mycolic acids are key factors participating in cell envelope permeability, host immunomodulation and persistence of M. tuberculosis. While several antitubercular agents inhibit mycolic acid synthesis, to date, the CMASs have not been shown to be drug targets. METHODOLOGY/PRINCIPLE FINDINGS: We have employed various complementary approaches to show that the antitubercular drug, thiacetazone (TAC), and its chemical analogues, inhibit mycolic acid cyclopropanation. Dramatic changes in the content and ratio of mycolic acids in the vaccine strain Mycobacterium bovis BCG, as well as in the related pathogenic species Mycobacterium marinum were observed after treatment with the drugs. Combination of thin layer chromatography, mass spectrometry and Nuclear Magnetic Resonance (NMR) analyses of mycolic acids purified from drug-treated mycobacteria showed a significant loss of cyclopropanation in both the alpha- and oxygenated mycolate sub-types. Additionally, High-Resolution Magic Angle Spinning (HR-MAS) NMR analyses on whole cells was used to detect cell wall-associated mycolates and to quantify the cyclopropanation status of the cell envelope. Further, overexpression of cmaA2, mmaA2 or pcaA in mycobacteria partially reversed the effects of TAC and its analogue on mycolic acid cyclopropanation, suggesting that the drugs act directly on CMASs. CONCLUSIONS/SIGNIFICANCE: This is a first report on the mechanism of action of TAC, demonstrating the CMASs as its cellular targets in mycobacteria. The implications of this study may be important for the design of alternative strategies for tuberculosis treatment.

Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria. Publishing Authors By Initials

A Alahari,X Trivelli,Y ,LG Dover,GS Besra,JC Sacchettini,RC Reynolds,GD Coxon,L Kremer,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: PLoS ONE

VOLUME: 2

Page Numbers: e1343

Journal Abbreviation: PLoS ONE

ISSN: 1932-6203

DAY: 19

MONTH: 12

YEAR: 2007

Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101285081

Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria.

AFFILIATION: Laboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Université de Montpellier II et I, Centre National de la Recherche Scientifique (CNRS), UMR 5235, Montpellier, France.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: PLoS ONE

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria Related Publications

• Challenges After Curative Treatment for Childhood Cancer and Long-Term Follow up of Survivors.
• Chloroplast DNA footprints of postglacial recolonization by oaks.
• Determinants of the choice for single or double embryo transfer in twin prone couples.
• Development of a genotyping microarray for Usher syndrome.
• EmbR2, a structural homologue of EmbR, inhibits the Mycobacterium tuberculosis kinase/substrate pair PknH/EmbR.
• Fokker-Planck-type equations for a simple gas and for a semirelativistic Brownian motion from a relativistic kinetic theory.
• Functional role of the PE domain and immunogenicity of the Mycobacterium tuberculosis triacylglycerol hydrolase LipY.
• Further studies on the utilization of I,3-butanediol as a source of energy in parenteral nutrition.
• Guideline-based development of quality indicators for subfertility care.
• High Mycobacterium bovis genetic diversity in a low prevalence setting.
• Identification of a specific limitation on local-feedback recurrent networks acting as Mealy-Moore machines.
• Interactions between human plasma components and a xenogenic adenovirus vector: reduced immunogenicity during gene transfer.
• Kinetics of TmHU binding to DNA as observed by optical tweezers.
• Luetic myocarditis; observations on pathology and problem of establishing a true clinical entity.
• MYO15A (DFNB3) mutations in Turkish hearing loss families and functional modeling of a novel motor domain mutation.
• Mutations of ESRRB Encoding Estrogen-Related Receptor Beta Cause Autosomal-Recessive Nonsyndromic Hearing Impairment DFNB35.
• No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial.
• Sinus CT Scan Findings in "Sinus Headache" Migraineurs.
• Structure-property relationships in major ampullate spider silk as deduced from polarized FTIR spectroscopy.
• Superconductivity in heavy alkaline-Earth intercalated graphites.
• Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria.
• Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
• Treatment of nephrosis with concentrated human serum albumin; effects on the proteins of body fluids.
• [Gynecological cytodiagnosis with screening (a solution from necessity)]
• [HEART DEFECT AND PREGNANCY.]
• [Indications and results of cesarean section 1944-53.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Report of two cases of familial cutaneous and mucosal hyalinosis (lipoid proteinosis).]